Partnership to advance investigational amyloid PET imaging biomarker
Click Here to Manage Email Alerts
A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.
According to a joint press release from Meilleur Technologies Inc. and PharmaLogic Holdings Corp., the latter will develop fluorine-18 [F18]NAV4694 for use in clinical trials at select United States-based radiopharmacies.
“We are delighted that the NAV4694 clinical and research program will be supported by PharmaLogic's extensive PET manufacturing and dispensing expertise,” Meilleur President and CEO Rick Hiatt said in the release. “Our goal is to expand the availability of this novel investigational imaging agent to the broader scientific community.”
Meilleur’s previously released biomarker, NAV-4694, was a best-in-class, second-generation amyloid-beta imaging biomarker that allowed for detection and validation of disease-modifying therapies with a high degree of precision and accuracy in determining risk of Alzheimer’s disease, per the release.
“PharmaLogic is pleased to partner with Meilleur Technologies, furthering our commitment to help combat some of the world's most challenging diseases, including Alzheimer’s disease,” PharmaLogic CEO Steve Chilinski said in the release.